Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14652190 | 0.85 | PKM (0.33) | PKMPDK1PDK2PDK3PDK4 | |
| SCHEMBL14652109 | 0.83 | PKM (0.40) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL15906218 | 0.83 | EPHX1 (0.43) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652133 | 0.81 | PKM (0.39) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652188 | 0.81 | PKM (0.39) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652185 | 0.80 | PKM (0.38) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652116 | 0.77 | PKM (0.43) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652052 | 0.76 | PKM (0.42) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652022 | 0.76 | PKM (0.42) | PKMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL14652181 | 0.75 | ALDH1A1 (0.41) | PKMALDH1A1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | PKM 445/4885ALDH1A1 3447/4885PDK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.